Trastuzumab Deruxtecan
Commons · Question 74361 · Tabled 2 Sep 2025 · Department of Health and Social Care · Official record
Answered 29 Oct 2025
Question
Asked by Gregory Stafford
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of Enhertu for the treatment of (a) HER2-positive and (b) HER2-low breast cancer.
Answer
Answered by Zubir Ahmed, 29 Oct 2025
The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an evaluation of a treatment’s...